ELTP Stock Overview
A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Elite Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.56 |
| 52 Week High | US$0.75 |
| 52 Week Low | US$0.12 |
| Beta | 0.17 |
| 11 Month Change | -4.02% |
| 3 Month Change | 187.95% |
| 1 Year Change | 255.83% |
| 33 Year Change | 1,434.15% |
| 5 Year Change | 531.61% |
| Change since IPO | -71.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELTP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.8% | -5.7% | -2.1% |
| 1Y | 255.8% | 9.0% | 29.6% |
Return vs Industry: ELTP exceeded the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: ELTP exceeded the US Market which returned 29.6% over the past year.
Price Volatility
| ELTP volatility | |
|---|---|
| ELTP Average Weekly Movement | 17.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ELTP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ELTP's weekly volatility has increased from 11% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 64 | Nasrat Hakim | www.elitepharma.com |
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases.
Elite Pharmaceuticals, Inc. Fundamentals Summary
| ELTP fundamental statistics | |
|---|---|
| Market cap | US$599.84m |
| Earnings (TTM) | -US$6.39m |
| Revenue (TTM) | US$71.17m |
8.4x
P/S Ratio-93.9x
P/E RatioIs ELTP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELTP income statement (TTM) | |
|---|---|
| Revenue | US$71.17m |
| Cost of Revenue | US$39.34m |
| Gross Profit | US$31.83m |
| Other Expenses | US$38.22m |
| Earnings | -US$6.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.006 |
| Gross Margin | 44.73% |
| Net Profit Margin | -8.98% |
| Debt/Equity Ratio | 15.7% |
How did ELTP perform over the long term?
See historical performance and comparison